Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Pleural Mesothelioma Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

10 recruiting trials for Pleural Mesothelioma. Eligibility criteria explained in plain English.

TrialFinderData lists 10 Pleural Mesothelioma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 33% (2 studies); the largest phase groups are Phase 2: 2, Phase 1: 2, Phase 1 / Phase 2: 2.

Research is led by Sun Yat-sen University (1), University Hospital, Angers (1), Aalborg University Hospital (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin (drug, 1 trial), followed by Drug skin tests (investigating hypersensitivity to a biotherapy), [68Ga]Ga-FAPI-46 PET/CT.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
10
Total Trials
10
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Track Pleural Mesothelioma trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 2NCT05930665

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural...

Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety...

Sponsor: Sun Yat-sen UniversityEnrolling: 381 location
RECRUITINGNCT06971848

Evaluation of Skin Tests in Biotherapy Allergies

Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory...

Sponsor: University Hospital, AngersEnrolling: 701 location
RECRUITINGPhase 2NCT06790082

The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma

Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET/CT at primary staging....

Sponsor: Aalborg University HospitalEnrolling: 701 location
RECRUITINGPhase 1NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in...

Sponsor: IDEAYA BiosciencesEnrolling: 26014 locations
RECRUITINGPhase 1 / Phase 2NCT05086692

A Beta-only IL-2 ImmunoTherapY Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor...

Sponsor: Medicenna Therapeutics, Inc.Enrolling: 11520 locations
RECRUITINGNCT05538806

TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study

The purpose of this post-authorisation medical device study is to obtain real life data on the use of Tumor Treating Fields (TTFields) in patients with pleural mesothelioma in...

Sponsor: NovoCure Ltd.Enrolling: 19820 locations
RECRUITINGPhase 1 / Phase 2NCT06362369

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens....

Sponsor: 7 Hills Pharma, LLCEnrolling: 1265 locations
RECRUITINGNCT05628376

TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO

TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung...

Sponsor: University College, LondonEnrolling: 6001 location
RECRUITINGPhase 1NCT06726564

A Study of MT027 in Patients with Pleural Malignant Tumors

This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional...

Sponsor: Suzhou Maximum Bio-tech Co., Ltd.Enrolling: 181 location
RECRUITINGNCT07403630

INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN...

This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk. The study...

Sponsor: Azienda Ospedaliero-Universitaria di ParmaEnrolling: 3002 locations

Frequently Asked Questions

There are currently 10 clinical trials for Pleural Mesothelioma, with 10 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Pleural Mesothelioma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Pleural Mesothelioma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.